American Research & Management Co. reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.1% in the first quarter, Holdings Channel.com reports. The institutional investor owned 25,193 shares of the company’s stock after selling 275 shares during the period. American Research & Management Co.’s holdings in Novo Nordisk A/S were worth $1,699,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently modified their holdings of the company. Childress Capital Advisors LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth $35,000. Capital Asset Advisory Services LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth $46,000. Perigon Wealth Management LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth $47,000. Sage Private Wealth Group LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth $60,000. Finally, Truvestments Capital LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth $67,000. Hedge funds and other institutional investors own 5.91% of the company’s stock.
Several research firms have recently issued reports on NVO. Deutsche Bank Aktiengesellschaft began coverage on Novo Nordisk A/S in a research note on Friday, January 15th. They issued a “buy” rating for the company. Credit Suisse Group cut Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Wednesday, January 20th. Barclays reissued an “overweight” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 4th. Finally, UBS Group restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Thursday, February 11th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. Novo Nordisk A/S has an average rating of “Hold” and an average price target of $72.00.
Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 2nd. The company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $3.41. The firm had revenue of $5.15 billion during the quarter, compared to the consensus estimate of $4.91 billion. Novo Nordisk A/S had a return on equity of 71.46% and a net margin of 32.65%. As a group, analysts forecast that Novo Nordisk A/S will post 2.78 EPS for the current year.
The firm also recently disclosed a semi-annual dividend, which was paid on Wednesday, April 7th. Investors of record on Monday, March 29th were paid a $0.9494 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.78. This represents a yield of 1.3%. The ex-dividend date was Friday, March 26th. Novo Nordisk A/S’s dividend payout ratio is currently 54.07%.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
Recommended Story: How are the companies in the S&P 500 selected?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.